Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2007733 | Peptides | 2007 | 12 Pages |
Abstract
We have utilized a rat model of peripheral artery disease (PAD) to examine whether the known angiogenic activity of the Y2 receptor would translate into a meaningful increase in collateral blood flow. The maximal increase in collateral blood flow capacity of ∼60% (p < 0.001) was obtained with a 10 μg/kg day (IA infusion, 14 days) of either PYY or PYY3–36 and did not differ from that obtained with a maximally angiogenic dose of VEGF165. Pharmacodynamic modeling based upon single dose pharmacokinetic plasma profiles of both agonists suggests that Emax is reached when the Y2 receptor is occupied by ≥50%. Furthermore, for PYY3–36, occupancy of the Y2 receptor is sufficient to promote a significant benefit in collateral blood flow.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Charles A. Cruze, Frank Su, Brian J. Limberg, Angela J. Deutsch, Peter J. Stoffolano, H. Jian Dai, Danielle D. Buchanan, H.T. Yang, Ronald L. Terjung, Russell D. Spruell, Scott W. Mittelstadt, Jan S. Rosenbaum,